fig5

From: Conjugated oligoelectrolytes overcome cancer drug resistance by dual-mode lysosomal membrane disruption

Figure 5. PTTP-DC6 triggers lysosomal impairment via a dual mode of action. (A) Three-dimensional PCA score plot of samples; (B and C) Volcano plots display DEPs in DC-6 vs. Blank and DC-6-L vs. Blank comparisons; (D) BP enrichment of DEPs in DC-6 vs. Blank; (E) BP enrichment of DEPs in DC-6-L vs. Blank; (F) Expression levels of lysosomal membrane proteins and ROS metabolism-related proteins (one-way ANOVA with Tukey’s test, ^*P< 0.05; ^**P < 0.01; ^***P < 0.001; ^****P < 0.0001. ns: no significance). PTTP-DC6: Benzene-pyridothiadiazole-thienothiophene-pyridothiadiazole-benzene conjugated framework with quaternary ammonium-terminated C6 alkyl chains at both ends; PCA: principal component analysis; DEPs: differentially expressed proteins; BP: biological process; ROS: reactive oxygen species; ANOVA: analysis of variance.